[Effect of interferon on malignant brain tumor].
The purpose of this investigation is to elucidate antitumor activity of human interferon-beta (Hu IFN-beta) against nervous system tumors. The study of growth inhibition in vitro with IFN against a variety of human glioma and neuroblastoma cell lines showed a significant response with sensitive cell lines at the concentration of 1 X 10(3) IU/ml in the medium. With resistant cell lines, however, tumor cells were proliferated as control even at the concentration of 10(4) IU/ml. The activation of lymphocyte-mediated cytotoxicity was also studied. The microcytotoxicity test with AJ glioma cells as target was used to evaluate it. In this system, percentage of cytotoxicity was 33 +/- 10.0% by lymphocytes obtained from six healthy adult men and four patients with malignant glioma, and it was increased to 71 and 72% seven days after intravenous administration of IFN (daily dose 3 X 10(6) IU) for the treatment of gliomas. The results indicate that human IFN-beta is considered effective in the treatment of malignant gliomas.
D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008938:Mitosis / Q000187:drug effects
D007370:Interferon Type I